3L9N
crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 27
Summary for 3L9N
Entry DOI | 10.2210/pdb3l9n/pdb |
Related | 3L9L 3L9M |
Descriptor | cAMP-dependent protein kinase catalytic subunit alpha, cAMP-dependent protein kinase inhibitor alpha, (2S)-N~1~-[5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl]-3-(4-methylphenyl)propane-1,2-diamine, ... (4 entities in total) |
Functional Keywords | pkb, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) More |
Cellular location | Cytoplasm (By similarity): P17612 |
Total number of polymer chains | 2 |
Total formula weight | 43390.48 |
Authors | Huang, X. (deposition date: 2010-01-05, release date: 2011-01-19, Last modification date: 2023-09-06) |
Primary citation | Zeng, Q.,Allen, J.G.,Bourbeau, M.P.,Wang, X.,Yao, G.,Tadesse, S.,Rider, J.T.,Yuan, C.C.,Hong, F.T.,Lee, M.R.,Zhang, S.,Lofgren, J.A.,Freeman, D.J.,Yang, S.,Li, C.,Tominey, E.,Huang, X.,Hoffman, D.,Yamane, H.K.,Fotsch, C.,Dominguez, C.,Hungate, R.,Zhang, X. Azole-based inhibitors of AKT/PKB for the treatment of cancer. Bioorg.Med.Chem.Lett., 20:1559-1564, 2010 Cited by PubMed: 20137943DOI: 10.1016/j.bmcl.2010.01.067 PDB entries with the same primary citation |
Experimental method |
Structure validation
Download full validation report